Intrathecal ketorolac pretreatment reduced spinal cord ischemic injury in rats

Anesthesia and Analgesia

Volumn 100, Issue 4, 2005, Pages 1134-1139

  Hsieh, Ying Chou ^a,c   Liang, Wen Yi ^c   Tsai, Shen Kou ^c   Wong, Chih Shung ^b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

KETOROLAC; PROSTAGLANDIN SYNTHASE INHIBITOR; SODIUM CHLORIDE;

ABDOMINAL AORTA ANEURYSM; ANEURYSM SURGERY; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; HINDLIMB; HISTOPATHOLOGY; LUMBAR SPINAL CORD; MALE; MOTOR PERFORMANCE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; POSTOPERATIVE COMPLICATION; PREMEDICATION; PRIORITY JOURNAL; RAT; SPINAL CORD ISCHEMIA; SURVIVAL RATE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY WEIGHT; INJECTIONS, SPINAL; KETOROLAC; MALE; NEURONS; RATS; RATS, WISTAR; SPINAL CORD; SPINAL CORD ISCHEMIA; SURVIVAL;

EID: 15544383252     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000146962.91038.15     Document Type: Article

References (24)

1. Svensson LG. New and future approaches for spinal cord protection. Semin Thorac Cardiovasc Surg 1997;9:206-21.
2. Lapchak PA, Araujo DM, Song D, Zivin JA. Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia. Stroke 2001;32:1220-5.
3. Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclooxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997;17:2746-55.
4. Kinouchi H, Huang H, Arai S, et al. Induction of cyclooxygenase-2 messenger RNA after transient and permanent middle cerebral artery occlusion in rats: comparison with c-fos messenger RNA by using in situ hybridization. J Neurosurg 1999;91:1005-12.
5. Candelario-Jalil E, Alvarez D, Castaneda JM, et al. The highly selective cyclooxygenase-2 inhibitor DFU is highly neuroprotective when given several hours after transient cerebral ischemia in gerbils. Brain Res 2002;927:212-5.
6. Nakayama M, Uchimura K, Zhu RL, et al. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci USA 1998;95: 10954-9.
7. Wakita H, Tomimoto H, Akiguchi I, et al. Cyclooxygenase-2 inhibitor attenuates white matter damage in chronic cerebral ischemia. Neuroreport 1999;10:1461-5.
8. Conklin DR, Eisenach JC. Intrathecal ketorolac enhances antinociception from clonidine. Anesth Analg 2003;96:191-4.
9. Ma W, Du W, Eisenach JC. Intrathecal lidocaine reverses tactile allodynia caused by nerve injuries and potentiates the antiallodynic effect of the COX inhibitor ketorolac. Anesthesiology 2003;98:203-8.
10. Eisenach JC, Curry R, Hood DD, Yaksh TL. Phase I safety assessment of intrathecal ketorolac. Pain 2002;99:599-604.
11. Yaksh TL, Rudy TS. Chronic catheterization of the spinal sub-arachnoid space. Physiol Behav 1976;17:1031-6.
12. Taira Y, Marsala M. Effect of proximal arterial perfusion pressure on function, spinal cord blood flow, and histopathological changes after increasing intervals of aortic occlusion in the rat. Stroke 1996;27:1850-8.
13. Marsala M, Yaksh TL. Transient spinal ischemia in the rat: characterization of behavioral and histopathological consequences as a function of the duration of aortic occlusion. J Cereb Blood Flow Metab 1994;14:526-35.
14. Jett MF, Ramesha CS, Brown CD, et al. Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. J Pharmacol Exp Ther 1999;288:1288-97.
15. Beiche F, Brune K, Geisslinger G, Goppelt-Struebe M. Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis. Inflamm Res 1998; 47:482-7.
16. Rooks WH. The pharmacologic activity of ketorolac tromethamine. Pharmacotherapy 1990;10:30S-2.
17. Chen J, Weinstein PR, Graham SH. Attenuation of postischemic brain hypoperfusion and reperfusion injury by the cyclooxygenase-lipoxygenase inhibitor BW755C. J Neurosurg 1995;83:99-104.
18. Buccellati C, Folco GC, Sala A, et al. Inhibition of prostanoid synthesis protects against neuronal damage induced by focal ischemia in rat brain. Neurosci Lett 1998;257:123-6.
19. Lin H, Lin TN, Cheung WM, et al. Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction. Circulation 2002;105:1962-9.
20. Schwab JM, Nguyen TD, Postler E, et al. Selective accumulation of cyclooxygenase-1-expressing microglial cells/macrophages in lesions of human focal cerebral ischemia. Acta Neuropathol (Berl) 2000;99:609-14.
21. Candelario-Jalil E, Conzalez-Falcon A, Garda-Cabrera M, et al. Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following global cerebral ischemia. J Neurochem 2003;86:545-55.
22. Korkmaz HA, Maltepe F, Erbayraktar S, et al. Antinociceptive and neurotoxicologic screening of chronic intrathecal administration of ketorolac tromethamine in the rat. Anesth Analg 2004;98:148-52.
23. Jaquenod M, Ronnhedh C, Cousins MJ, et al. Factors influencing ketorolac-associated perioperative renal dysfunction. Anesth Analg 1998;86:1090-7.
24. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119: 706-14.